Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time
NEW YORK–(BUSINESS WIRE)–Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today that it will present a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.
Poster Presentation Details
Title: Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
Date and time: Saturday, June 4, 2022, 8:00 a.m. CDT
Session: Gastrointestinal Cancer—Colorectal and Anal
Abstract ID: 3579
About Inspirna
Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer high unmet progression. The company is pursuing several first-in-class drug candidates to treat cancers of need. Inspirna’s lead drug candidate RGX-202 is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients with gastrointestinal cancers where it enables the generation of the energy molecule ATP in response to tumor hypoxia. RGX-202 is currently being tested in a Phase 1b clinical trial in combination with standard-of-care FOLFIRI and bevacizumab for the second line treatment of patients with advanced CRC. Inspirna expects to present data from this clinical study in mid-2022.
Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVErTM, which was originally developed by Inspirna’s scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers. The Company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Sixty Degree Capital, K2 HealthVentures, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit www.inspirna.com.
Contacts
Argot Partners
Maeve Conneighton
212-600-1902
inspirna@argotpartners.com